Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2021-12-13 Share Issue/Capital Cha…
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 1% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly states the number of shares and theoretical voting rights as of November 30, 2021, referencing French regulatory articles (Code de commerce and AMF). This type of regular disclosure regarding the total share capital and voting rights is a specific regulatory requirement in France. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the composition of the share capital, although it is a monthly update rather than a major change announcement. However, given the specific nature of reporting total voting rights and shares, and the lack of a dedicated code for 'Monthly Share Capital Update', 'SHA' is the most appropriate classification for changes/updates related to the share structure. The document is short and self-contained, not an announcement of a larger report.
2021-12-13 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 1% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly states the date (November 15, 2021) and provides a table detailing the number of shares and theoretical voting rights as of October 31, 2021, referencing French regulatory articles (AMF). This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement in France. Among the provided codes, this content most closely aligns with a notification regarding capital structure changes or a mandatory periodic filing. Since it is a monthly update on the total number of shares and voting rights, it relates directly to the company's capital structure. The closest fit among the options is 'Share Issue/Capital Change' (SHA), although it is a periodic disclosure rather than a specific issuance event. However, given the options, 'SHA' covers changes/updates to the capital structure. If a more specific 'Capital Update' existed, it might fit better, but 'SHA' is the most relevant category for share count disclosures. It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS) as it is highly specific to share count.
2021-11-15 French
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT". It details the cash position (€12.5 M), announces a key management change (appointment of CMO), and provides updates on clinical programs (THN 102 and BBDF 101). This content structure—financial highlights, management changes, and operational progress updates—is characteristic of an Earnings Release (ER) or a comprehensive Interim/Quarterly Report (IR). Since it provides specific financial figures (€12.5 M cash position) and operational updates, it goes beyond a simple announcement of results. However, it is not a full, audited financial statement (like a 10-K or IR). Given the focus on key financial metrics and operational progress following a period end (September 30th), it most closely aligns with an Earnings Release (ER) which typically contains these highlights, or potentially an Interim Report (IR) if it were more comprehensive. Since it is a press release format announcing results and progress, ER is the most fitting category for initial periodic financial announcements. 9M 2021
2021-10-19 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2021 ET FAIT LE POINT SUR SES AVANCÉES
Earnings Release Classification · 1% confidence The document is a press release dated October 19, 2021, titled "THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2021 ET FAIT LE POINT SUR SES AVANCÉES" (Theranexus publishes its cash position as of September 30, 2021, and provides an update on its progress). It contains two main components: 1) A financial update (cash position as of 30/09/2021) and 2) An announcement regarding senior management change (appointment of a new Medical Director) and clinical pipeline updates (THN 102 and BBDF 101). This structure—combining key financial metrics for a period end (though not a full quarterly report) with significant operational/personnel news—is characteristic of an Earnings Release (ER) or a general operational update that often accompanies an ER. Since it focuses on the cash position and operational progress rather than being a full, comprehensive quarterly report (IR) or a transcript (CT), 'ER' (Earnings Release) is the most appropriate fit for the initial financial highlight, even though it also contains management news. It is not a formal regulatory filing like a 10-K or IR, but rather a public announcement of results/updates. 9M 2021
2021-10-19 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital) and is dated October 1, 2021, referencing data as of September 30, 2021. It explicitly cites French regulatory articles (L. 233-8 II du code de commerce and 223-16 du règlement général de l'AMF - Autorité des marchés financiers). This type of mandatory monthly disclosure regarding the total number of shares and voting rights is a specific regulatory requirement in France. Among the provided codes, none perfectly match a 'Monthly Voting Rights Disclosure'. However, this filing relates to the structure of the company's capital and voting rights, which is a fundamental aspect of corporate governance and share structure reporting. It is not an earnings release (ER), an interim report (IR), a director's dealing (DIRS), or a capital change announcement (CAP) in the sense of fundraising. Since it is a mandatory regulatory disclosure that doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate general category for mandatory regulatory updates that aren't standard financial reports or management changes is 'Regulatory Filings' (RNS). Alternatively, given the focus on share capital and voting rights, it touches upon 'Share Issue/Capital Change' (SHA), but SHA usually implies an action (issue/split), whereas this is a periodic status report. Given the context of mandatory French regulatory reporting on share capital structure, RNS serves as the best fit among the available options for a non-standard, periodic regulatory update.
2021-10-01 French
RAPPORT SEMESTRIEL 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT SEMESTRIEL' (Semi-Annual Report) for the company Theranexus. It contains detailed financial and operational information, including a summary of activities, management discussion, and references to financial statements for the first semester. It is a comprehensive report rather than a short announcement, fitting the definition of an Interim/Quarterly Report. H2 2021
2021-09-30 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.